About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT06642610

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.

Lead sponsor: Indiana University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Eslam Montaser, PhD

CONTACT

4344660570 [email protected]

Sponsors

Lead Sponsor

Indiana University

Age

12 - 55 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•CF individuals aged 12-55 years.
•CF without diabetes or with prediabetes (as defined by OGTT and HbA1c).
•Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection.
•A person with CFRD and already using CGM, we will just collect their personal CGM data, and they are not required to have OGTT or HbA1c visit.

Exclusion Criteria

•Pregnancy.
•History of transplant.
•Use of immunosuppressant drugs.
•Use of oral steroids or any medication known to interfere with glucose.
•Allergy to adhesives.
•Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure).
•Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator

Related studies

RECRUITINGPhase 2

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

NCT04530383 · Cystic Fibrosis-related Diabetes, Cystic Fibrosis

The Bialystok Bariatric Surgery Study

NCT04634591 · Obesity, Diabetes Mellitus, and more

Dinner Time for Obesity and Prediabetes

NCT05745441 · PreDiabetes, Obesity, and more

RECRUITINGPhase 2

Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

NCT07286747 · Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Physical Impairments in Children With Cystic Fibrosis

NCT06984679 · Cystic Fibrosis (CF), Cystic Fibrosis in Children

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 29, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment70

Start dateJun 2025

Last updatedJul 29, 2025

Condition

Prediabetes Cystic Fibrosis (CF)Cystic Fibrosis-related Diabetes

Locations shown

Indiana University Health, University Hospital

Indianapolis, Indiana

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions